EasyM – A personalized MS-based assay to monitor multiple 2 myeloma disease assessment facilitated by the Evosep One
This publication by the Trudel group describes the development of a non-invasive MS-based assay, called EasyM, which is used to assess minimal residual disease, a measure of depth of remission to treatment, which has become an important parameter in assessing the disease burden in multiple myeloma.
Facilitating early adequate therapy for patients infected by multidrug resistant bacteria calls for a novel precise and rapid diagnostic method as today’s resistance determinations are often slow and expensive.
Senior Scientific Advisor Thomas Angel at GSK presents Targeted assay development for quantifying protein half-life over a range of mouse tissues. Take me to the webinar